HC Wainwright Forecasts Strong Price Appreciation for Harrow (NASDAQ:HROW) Stock

Harrow (NASDAQ:HROW) had its price target increased by HC Wainwright from $57.00 to $60.00 in a report published on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, B. Riley lowered their price objective on shares of Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $26.66 on Monday. The firm’s 50 day moving average is $24.80 and its two-hundred day moving average is $32.36. Harrow has a 52 week low of $11.39 and a 52 week high of $59.23. The firm has a market capitalization of $978.02 million, a P/E ratio of -28.36 and a beta of 0.41. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Analysts anticipate that Harrow will post -0.53 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Barclays PLC boosted its holdings in Harrow by 301.9% during the third quarter. Barclays PLC now owns 52,593 shares of the company’s stock worth $2,365,000 after buying an additional 39,506 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Harrow by 443.1% during the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after buying an additional 194,480 shares in the last quarter. Brookstone Capital Management bought a new stake in Harrow during the fourth quarter worth approximately $275,000. SG Americas Securities LLC boosted its holdings in Harrow by 158.5% during the fourth quarter. SG Americas Securities LLC now owns 30,689 shares of the company’s stock worth $1,030,000 after buying an additional 18,815 shares in the last quarter. Finally, Sonora Investment Management Group LLC bought a new stake in Harrow during the fourth quarter worth approximately $518,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.